Osimertinib (AZD9291) is an Orally Active EGFR Inhibitor for Lung Cancer Research
EGFR-mutated (EGFRm+) non-small cell lung cancer (NSCLC) is a major clinical problem. Tyrosine kinase inhibitors (TKIs) have precision therapeutic implications for advanced NSCLC. However, common EGFR mutations, such as EGFRL858R,…